Get the latest Science News and Discoveries
Newly identified PET biomarker predicts success of immune checkpoint blockade therapy - EurekAlert
The protein galectin-1 (Gal-1) has been identified as a new PET imaging biomarker for immune checkpoint blockade (ICB) therapy, allowing physicians to predict the tumor responses before beginning treatment. Information garnered from Gal-1 PET imaging could also be used to facilitate patient stratification and optimize immunotherapy, enabling targeted interventions and improving patient outcomes. This research was published in the May issue of <em>The Journal of Nuclear Medicine</em>.
None
Or read this on Eureka Alert
